Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650.
RPMI 2650
barrier model
nose-to-brain
olfactory epithelium
primary cells
respiratory epithelium
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
01 Aug 2019
01 Aug 2019
Historique:
received:
24
06
2019
revised:
18
07
2019
accepted:
20
07
2019
entrez:
4
8
2019
pubmed:
4
8
2019
medline:
4
8
2019
Statut:
epublish
Résumé
The epithelial layer of the nasal mucosa is the first barrier for drug permeation during intranasal drug delivery. With increasing interest for intranasal pathways, adequate in vitro models are required. Here, porcine olfactory (OEPC) and respiratory (REPC) primary cells were characterised against the nasal tumour cell line RPMI 2650. Culture conditions for primary cells from porcine nasal mucosa were optimized and the cells characterised via light microscope, RT-PCR and immunofluorescence. Epithelial barrier function was analysed via transepithelial electrical resistance (TEER), and FITC-dextran was used as model substance for transepithelial permeation. Beating cilia necessary for mucociliary clearance were studied by immunoreactivity against acetylated tubulin. OEPC and REPC barrier models differ in TEER, transepithelial permeation and MUC5AC levels. In contrast, RPMI 2650 displayed lower levels of MUC5AC, cilia markers and TEER, and higher FITC-dextran flux rates. To screen pharmaceutical formulations for intranasal delivery in vitro, translational mucosal models are needed. Here, a novel and comprehensive characterisation of OEPC and REPC against RPMI 2650 is presented. The established primary models display an appropriate model for nasal mucosa with secreted MUC5AC, beating cilia and a functional epithelial barrier, which is suitable for long-term evaluation of sustained release dosage forms.
Sections du résumé
BACKGROUND
BACKGROUND
The epithelial layer of the nasal mucosa is the first barrier for drug permeation during intranasal drug delivery. With increasing interest for intranasal pathways, adequate in vitro models are required. Here, porcine olfactory (OEPC) and respiratory (REPC) primary cells were characterised against the nasal tumour cell line RPMI 2650.
METHODS
METHODS
Culture conditions for primary cells from porcine nasal mucosa were optimized and the cells characterised via light microscope, RT-PCR and immunofluorescence. Epithelial barrier function was analysed via transepithelial electrical resistance (TEER), and FITC-dextran was used as model substance for transepithelial permeation. Beating cilia necessary for mucociliary clearance were studied by immunoreactivity against acetylated tubulin.
RESULTS
RESULTS
OEPC and REPC barrier models differ in TEER, transepithelial permeation and MUC5AC levels. In contrast, RPMI 2650 displayed lower levels of MUC5AC, cilia markers and TEER, and higher FITC-dextran flux rates.
CONCLUSION
CONCLUSIONS
To screen pharmaceutical formulations for intranasal delivery in vitro, translational mucosal models are needed. Here, a novel and comprehensive characterisation of OEPC and REPC against RPMI 2650 is presented. The established primary models display an appropriate model for nasal mucosa with secreted MUC5AC, beating cilia and a functional epithelial barrier, which is suitable for long-term evaluation of sustained release dosage forms.
Identifiants
pubmed: 31374872
pii: pharmaceutics11080367
doi: 10.3390/pharmaceutics11080367
pmc: PMC6723747
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Horizon 2020 Framework Programme
ID : 721098
Organisme : Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
ID : FcRn in Drug Delivery
Organisme : Bundesministerium für Wirtschaft und Energie
ID : ALIVE
Organisme : Stiftung der Deutschen Wirtschaft
ID : fellowship to SL and JF
Références
Am J Respir Cell Mol Biol. 1999 Mar;20(3):500-10
pubmed: 10030849
J Membr Biol. 1999 Jul 15;170(2):147-56
pubmed: 10430658
Adv Drug Deliv Rev. 1998 Jan 5;29(1-2):13-38
pubmed: 10837578
Adv Drug Deliv Rev. 1998 Jan 5;29(1-2):51-79
pubmed: 10837580
Laryngoscope. 2000 Dec;110(12):2110-3
pubmed: 11129031
J Control Release. 2002 Feb 19;79(1-3):147-55
pubmed: 11853926
Differentiation. 2002 May;70(2-3):77-83
pubmed: 12076334
Am J Physiol Lung Cell Mol Physiol. 2003 Feb;284(2):L247-59
pubmed: 12533309
Drug Discov Today. 2002 Dec 1;7(23):1184-9
pubmed: 12547019
J Control Release. 2003 Feb 21;87(1-3):187-98
pubmed: 12618035
J Comp Neurol. 2003 Sep 29;464(4):511-24
pubmed: 12900921
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Microsc Res Tech. 1992 Oct 1;23(1):49-61
pubmed: 1392071
Cancer. 1964 Feb;17:170-5
pubmed: 14123677
Microsc Res Tech. 1992 Oct 15;23(2):111-27
pubmed: 1421551
J Pharm Sci. 2003 Dec;92(12):2399-410
pubmed: 14603485
Brain Res Brain Res Protoc. 2003 Oct;12(2):91-8
pubmed: 14613810
Pharm Res. 2003 Oct;20(10):1690-6
pubmed: 14620527
Drug Deliv. 2005 Sep-Oct;12(5):305-11
pubmed: 16188730
Arch Otolaryngol Head Neck Surg. 1992 Jul;118(7):731-8
pubmed: 1627295
Annu Rev Physiol. 2006;68:403-29
pubmed: 16460278
Toxicol Pathol. 2006;34(3):252-69
pubmed: 16698724
Neuroscience. 1991;41(2-3):617-28
pubmed: 1714553
J Virol Methods. 2007 Jun;142(1-2):105-12
pubmed: 17324473
Int J Pharm. 2007 Jun 7;337(1-2):1-24
pubmed: 17475423
Lancet Neurol. 2008 Jan;7(1):84-96
pubmed: 18093565
Eur J Pharm Biopharm. 2009 Feb;71(2):318-24
pubmed: 18845252
Science. 2009 Aug 28;325(5944):1131-4
pubmed: 19628819
Eur J Pharm Biopharm. 2010 Feb;74(2):290-7
pubmed: 19733661
Eur Respir J. 2010 Apr;35(4):894-903
pubmed: 19741028
Eur Respir J. 1991 Feb;4(2):210-7
pubmed: 2044738
Am J Physiol Lung Cell Mol Physiol. 2011 Jan;300(1):L25-31
pubmed: 20971803
Mol Biol Cell. 2011 Apr;22(7):1045-57
pubmed: 21307336
Neuropathol Appl Neurobiol. 1990 Jun;16(3):213-23
pubmed: 2169597
Chem Senses. 2012 Jan;37(1):35-46
pubmed: 21745799
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
pubmed: 22119441
Eur J Pharm Biopharm. 2012 Feb;80(2):465-9
pubmed: 22120685
Expert Opin Drug Deliv. 2012 Jan;9(1):19-31
pubmed: 22171740
Toxicol In Vitro. 2012 Apr;26(3):445-54
pubmed: 22274662
Influenza Other Respir Viruses. 2013 Mar;7(2):139-50
pubmed: 22530566
Curr Drug Deliv. 2012 Nov;9(6):566-82
pubmed: 22788696
J Clin Immunol. 2013 Jan;33 Suppl 1:S9-17
pubmed: 22948741
Am J Physiol Cell Physiol. 2012 Dec 1;303(11):C1173-9
pubmed: 23015550
J Pharm Pharmacol. 2012 Nov;64(11):1621-30
pubmed: 23058049
PLoS One. 2013;8(1):e53783
pubmed: 23326505
Expert Opin Drug Deliv. 2013 Jul;10(7):957-72
pubmed: 23586809
Drug Deliv. 2014 Mar;21(2):75-86
pubmed: 24102636
J Cell Biol. 1985 Dec;101(6):2085-94
pubmed: 2415535
BMC Cell Biol. 2014 May 06;15:14
pubmed: 24885012
Pharm Res. 2015 Feb;32(2):665-79
pubmed: 25145337
J Lab Autom. 2015 Apr;20(2):107-26
pubmed: 25586998
Histochem Cell Biol. 2015 Nov;144(5):509-15
pubmed: 26223877
Lung. 2016 Jun;194(3):419-28
pubmed: 27071933
Int J Pharm. 2016 Jul 11;508(1-2):22-33
pubmed: 27155589
In Vitro Cell Dev Biol. 1989 May;25(5):460-5
pubmed: 2732200
Acta Pharm Sin B. 2016 Jul;6(4):268-86
pubmed: 27471668
Int J Pharm. 2016 Dec 30;515(1-2):1-10
pubmed: 27702697
Acta Otolaryngol. 1989 Sep-Oct;108(3-4):259-67
pubmed: 2816340
Lab Chip. 2017 May 2;17(9):1578-1584
pubmed: 28379223
Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):13-24
pubmed: 28688000
Int J Pharm. 2017 Oct 30;532(1):537-546
pubmed: 28917988
Life Sci. 2018 Feb 15;195:44-52
pubmed: 29277310
Mol Pharm. 2018 Jun 4;15(6):2246-2256
pubmed: 29709196
Pharmaceutics. 2018 Jul 26;10(3):null
pubmed: 30050027
Pharmaceutics. 2018 Aug 03;10(3):null
pubmed: 30081536
J Neurosci Methods. 2019 Jan 1;311:133-146
pubmed: 30336221
Environ Pollut. 2019 May;248:736-742
pubmed: 30849591
Eur J Pharm Biopharm. 2019 Jun;139:186-196
pubmed: 30951820
Chem Senses. 2019 Sep 7;44(7):511-521
pubmed: 31300812
Exp Brain Res. 1986;63(3):461-73
pubmed: 3758265
J Comp Neurol. 1986 Sep 8;251(2):260-80
pubmed: 3782501
J Neurocytol. 1979 Feb;8(1):1-18
pubmed: 438867
Exp Cell Res. 1965 Aug;39(1):190-6
pubmed: 5831238
Differentiation. 1983;23(3):256-69
pubmed: 6189757
Chest. 1978 May;73(5):627-33
pubmed: 648216
Laryngoscope. 1983 Dec;93(12):1576-99
pubmed: 6645759
Brain Res. 1982 Dec 16;253(1-2):39-46
pubmed: 7150975
Acta Otolaryngol. 1995 Jan;115(1):66-70
pubmed: 7762388
J Cell Sci. 1995 Feb;108 ( Pt 2):431-40
pubmed: 7768991
Am J Respir Cell Mol Biol. 1994 Mar;10(3):271-7
pubmed: 8117445
Pharm Res. 1993 Jul;10(7):991-7
pubmed: 8378262
Pharm Res. 1996 Jul;13(7):978-88
pubmed: 8842033
Rhinology. 1995 Dec;33(4):194-8
pubmed: 8919210
Am J Rhinol. 1997 Jul-Aug;11(4):293-302
pubmed: 9292181
Glycobiology. 1997 Oct;7(7):965-73
pubmed: 9363439
Eur J Pharm Sci. 1999 Feb;7(3):197-206
pubmed: 9845806